Evidence map›Paper›PMID 30808675›Full record

ArticleCancer research2019

Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate.

Emily C Cox, Dana N Thornlow, Michaela A Jones, Jordan L Fuller, Judith H Merritt, Matthew J Paszek, Christopher A Alabi, Matthew P DeLisa

Abstract read
In one paragraph

Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Antibody-Biopolymer Conjugates in Oncology: A Review.Molecules (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Emily C CoxBiological and Biomedical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York.
Dana N ThornlowRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York.
Michaela A JonesRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York.
Jordan L FullerRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York.
Judith H MerrittGlycobia Incorporated, Ithaca, New York.
Matthew J PaszekRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York.
Christopher A AlabiRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York.
Matthew P DeLisaBiological and Biomedical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York. md255@cornell.edu.
Cornell University · USGlycobia (United States) · US

Funding

Project 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI SCHAFFER, CHRIS B · 2016 to 2020
$10.2M
Overall Priority Score P41GM103694 · NIGMS · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D · 2013 to 2018
$6.9M
CHEMISTRY OF BIOLOGICAL SYSTEMST32GM008500 · NIGMS · CORNELL UNIVERSITY ITHACA · PI LIN, HENING · 1996 to 2020
$5.4M
Protein-Glycan Interaction Resource of the CFGR24GM098791 · NIGMS · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D, PAULSON, JAMES C · 2011 to 2013
$2.6M
Broad wavelength range Zeiss 780 NLO/confocal system for the Cornell Imaging CoreS10OD018516 · OD · CORNELL UNIVERSITY · PI ZIPFEL, WARREN R · 2014 to 2014
$834k
High-throughput label-free detection system for biomolecular interaction analysisS10OD032273 · OD · CORNELL UNIVERSITY · PI DELISA, MATTHEW P · 2022 to 2022
$350k
NCI NIH HHS U54 CA210184NIGMS NIH HHS P41 GM103694NIGMS NIH HHS R24 GM098791NIGMS NIH HHS T32 GM008500NIH HHS S10 OD018516NIH HHS S10 OD032273
6 · The paper itself

Abstract

The specific targeting of differentially expressed glycans in malignant cells has emerged as an attractive anticancer strategy. One such target is the oncodevelopmental antigen polysialic acid (polySia), a polymer of α2,8-linked sialic acid residues that is largely absent during postnatal development but is re-expressed during progression of several malignant human tumors, including small-cell and non-small cell lung carcinomas, glioma, neuroblastoma, and pancreatic carcinoma. In these cancers, expression of polySia correlates with tumor progression and poor prognosis and appears to modulate cancer cell adhesion, invasiveness, and metastasis. To evaluate the potential of PolySia as a target for anticancer therapy, we developed a chimeric human polySia-specific mAb that retained low nanomolar (nmol/L) target affinity and exhibited exquisite selectivity for polySia structures. The engineered chimeric mAb recognized several polySia-positive tumor cell lines

Indexed as

EndocytosisAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalDrug Delivery SystemsGlycoproteinsHumansImmunoconjugatesIntracellular SpaceNeoplasmsPolysaccharidesSialic AcidsTrastuzumabTumor Cells, CulturedAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalGlycoproteinsImmunoconjugatesPolysaccharidespolysialic acidSialic AcidsTrastuzumab

Identifiers

PMID30808675
PMCPMC6467748
OpenAlexW2917331339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.